Please use this identifier to cite or link to this item:
|Title:||Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.|
|Authors:||Jonker, Derek J;Nott, Louise;Yoshino, Takayuki;Gill, Sharlene;Shapiro, Jeremy;Ohtsu, Atsushi;Zalcberg, John;Vickers, Michael M;Wei, Alice C;Gao, Yuan;Tebbutt, Niall C;Markman, Ben;Price, Timothy;Esaki, Taito;Koski, Sheryl;Hitron, Matthew;Li, Wei;Li, Youzhi;Magoski, Nadine M;Li, Chiang J;Simes, John;Tu, Dongsheng;O'Callaghan, Christopher J|
|Affiliation:||Department of Medicine, Division of Medical Oncology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada|
Medical Oncology, Royal Hobart Hospital, Hobart, Australia
Department of Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
Department of Medicine, Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
Department of Oncology, Cabrini Hospital, Melbourne, Australia
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia
Division of General Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Clinical Development, Boston Biomedical, Boston, MA, USA
Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Monash Cancer Centre, Monash Health, Melbourne, Australia
The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia
Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, Fukuoka, Japan
Department of Oncology, University of Alberta Cross Cancer Institute, Edmonton, AB, Canada
Clinical Development, Boston Biomedical, Boston, MA, USA..
Canadian Cancer Trials Group, Queens University, Kingston, ON, Canada..
1Globe Health Institute, Norwood, MA, USA; Boston Biomedical, Cambridge, MA, USA
NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
Department of Mathematics and Statistics, Queens University, Kingston, ON, Canada
Department of Public Health Sciences, Queens University, Kingston, ON, Canada
|Citation:||The lancet. Gastroenterology & hepatology 2018; online first: 31 January|
|Abstract:||Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3, which is a poor prognostic factor in colorectal cancer. This study aimed to test napabucasin in advanced colorectal cancer. This study was a double-blind randomised phase 3 trial done at 68 centres in Canada, Australia, New Zealand, and Japan. Patients with advanced colorectal cancer with a good Eastern Cooperative Oncology Group (ECOG) performance status (0-1) for whom all available standard therapies had failed were eligible for the study. Patients were randomly assigned (1:1) to receive placebo or napabucasin through a web-based system with a permuted block method, after stratification by ECOG performance status, KRAS status, previous VEGF inhibitor treatment, and time from diagnosis of metastatic disease. Napabucasin 480 mg or matching placebo was taken orally every 12 h. All patients received best supportive care. The primary endpoint was overall survival assessed in an intention-to-treat analysis. This is the final analysis of this trial, which is registered at ClinicalTrials.gov, number NCT01830621. Accrual began on April 15, 2013, and was stopped for futility on May 23, 2014, at which point 282 patients had undergone randomisation (138 assigned to the napabucasin group and 144 to the placebo group). Overall survival did not differ significantly between groups: median overall survival was 4·4 months (95% CI 3·7-4·9) in the napabucasin group and 4·8 months (4·0-5·3) in the placebo group (adjusted hazard ratio [HR] 1·13, 95% CI 0·88-1·46, p=0·34). The safety population included 136 patients in the napabucasin group and 144 patients in the placebo group. More patients who received napabucasin had any grade of treatment-related diarrhoea (108 [79%] of 136 patients), nausea (69 [51%]), and anorexia (52 [38%]) than did patients who received placebo (28 [19%] of 144 patients, 35 [24%], and 23 [16%], respectively). The most common severe (grade 3 or worse) treatment-related adverse events were abdominal pain (five [4%] patients receiving napabucasin vs five [3%] receiving placebo), diarrhoea (21 [15%] vs one [1%]), fatigue (14 [10%] vs eight [6%]), and dehydration (six [4%] vs one [1%]). 251 (89%) patients had data on pSTAT3 expression, of whom 55 (22%) had pSTAT3-positive tumours (29 in the napabucasin group, 26 in the placebo group). In a prespecified biomarker analysis of pSTAT3-positive patients, overall survival was longer in the napabucasin group than in the placebo group (median 5·1 months [95% CI 4·0-7·5] vs 3·0 months [1·7-4·1]; HR 0·41, 0·23-0·73, p=0·0025). Although there was no difference in overall survival between groups in the overall unselected population, STAT3 might be an important target for the treatment of colorectal cancer with elevated pSTAT3 expression. Nevertheless, these results require validation. Canadian Cancer Society Research Institute and Boston Biomedical.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.